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More than 360 million persons worldwide (6% of the world pop-
ulation) are chronically infected by the hepatitis B virus (HBV).
Although the incidence of HBV infection has dramatically
declined since the implementation of universal immunization
programs in several countries and blood-donor screening, a sig-
niﬁcant number of children are still infected each year, often
developing chronic infection and requiring appropriate follow-
up [1]. Despite a rather benign course of chronic hepatitis B
(CHB) during childhood and adolescence, 3–5% and 0.01–0.03%
of chronic carriers develop cirrhosis or hepatocellular carcinoma
(HCC), respectively, before adulthood [2,3]. Such a risk for HCC
rises to 9–24% when considering the whole lifetime, with an inci-
dence of cirrhosis of 2–3% per year [4,5]. Worldwide universal
vaccination remains the goal for eliminating HBV infection and
its complications. Treatment of CHB in childhood has been ham-
pered by the chronic delay in licensing new drugs for pediatric
use. Safe and effective antiviral therapies are available in adults,
but few are labeled for the use in children, and an accurate selec-
tion of whom to treat and the identiﬁcation of the right timing forJournal of Hepatology 20
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antiviral resistance. Although several guidelines on the manage-
ment of adult patients with CHB have been published by major
international societies, the clinical approach to infected children
is still evolving, and is mostly based on consensus of expert opin-
ion [6–9].
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Context
Epidemiology and prevention
Since the WHO recommended global immunization programs for
HBV in 1991, the prevalence of HBV infection has declined world-
wide [5,10–12]. Although among children born in Western Eur-
ope and North America HBsAg-positivity is rare, pediatricians
are confronted with an increasing number of children adopted
from higher prevalence countries, 2–5% of whom are still infected
with HBV and often carry HBV genotypes which expose them to a
higher risk of complications [1,13–15].
In countries where donor screening and blood testing have
been implemented, the current risk of acquiring HBV infection
after blood transfusion is estimated at 1 in 500,000 per unit expo-
sure [16,17]. Nevertheless, as HBV nosocomial transmission is
still a critical problem, vaccination status of children needs to
be checked regularly and all preventive measures have to be
strictly respected [18].
Mother-to-child transmission accounts for more than 50% of
chronic infections in highly endemic areas. After exposure, the
risk of chronicity is higher for newborns (90%), infants and chil-
dren younger than 5 years (25–30%) than for adolescents or
adults (<5%) [19,20].
Vaccination is the most effective measure to prevent hepatitis
B transmission. In highly endemic areas, it is also the most13 vol. 59 j 814–829
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cost-effective medical intervention, offering the higher beneﬁt-
cost ratio, whereas in low-endemicity countries, such cost-effec-
tiveness is not as clear [21–24]. Recombinant vaccine induces a
seroprotective response (anti-HBs P10 mIU/ml) in about 95% of
subjects vaccinated with three doses [25,26]. The ﬁrst dose of
monovalent vaccine should be administered intramuscularly
within 24 hours of birth, and should be followed by 2 or 3 doses
(monovalent or combined) with a minimum interval of 4 weeks
(A1) [26]. Preterm infants weighting <2000 g should receive 3
doses after the birth dose (B1) [26,147]. Postvaccination testing
for a protective concentration of anti-HBs is recommended only
for high-risk populations (infants born to HBsAg-positive moth-
ers and HIV-infected or other immunocompromised subjects),
and should be performed 1–2 months after the end of the vacci-
nation schedule (A1) [26]. Revaccination with further 3 doses
induces protective anti-HBs response in the majority of non-
responders [27,28]. Immunocompromised subjects should be
tested annually and revaccinated if anti-HBs <10 mIU/ml (C1)
[148]. Although anti-HBs levels have been shown to decrease
over time, long-lasting protection has been observed in vacci-
nated subjects with undetectable anti-HBs, and at present there
is no clear evidence for recommending the administration of a
booster dose in immunocompetent individuals [149,150]. Testing
for coeliac disease, HIV or other causes of immune deﬁciency
might be advisable for non-responders (C2) [29,30,151].
Vaccine failure and mother-to-child transmission of hepatitis
B affect 17% of infants born to HBeAg-positive mothers [25]. The
high viral load related to HBeAg-positivity seems to be the most
important factor for breakthrough infection [25,31]. Moreover,
when the mother is infected by genotype C HBV, intrauterine
infection may occur before vaccination can be administred, in
addition to hyporesponsivness to vaccination [31,32]. When the
mother is a chronic carrier, vaccination at birth is not sufﬁcient
to avoid vertical transmission, and concurrent intramuscular
administration of 0.5 ml of hepatitis B immunoglobulin (HBIG)
is recommended to give immediate passive immunity to the
newborn [26,33]. Administration of both the vaccine and HBIG
to newborns of HBeAg-positive mothers within 12–24 h of birth
allows the achievement of 90% protection rate (98% when moth-
ers are HBeAg-negative), compared to vaccine alone [25,26,34].
Administration of both vaccine and HBIG is recommended for
newborns of HBeAg-positive mothers (A1). Although a clear ben-
eﬁt has not been shown for newborns of HBeAg-negative moth-
ers, a reduction of the incidence of fulminant hepatitis justiﬁes
HBIG administration to all infants born of HBsAg-positive moth-
ers [25], regardless of the maternal HBeAg status (C2). High
breakthrough infection (17%) and chronicity (54%) rates have
been reported in newborns of HBeAg-positive mothers despite
concomitant active and passive immunization at birth [25]. As
breakthrough infection rates are directly correlated to maternal
viral load (as well as to HBV genotype C, high HBsAg titer, vaginal
delivery, hyporesponsiveness to vaccine and vaccine escape
mutants) [25,31,152], treatment with nucleos(t)ide analogues
(NA) of highly viraemic women during the last trimester of preg-
nancy is currently recommended to prevent vertical transmission
(B1, see below) [8].
Breastfeeding has been shown not to contribute signiﬁcantly
to HBV transmission from infected mothers to infants who have
received active and passive immunoprophylaxis [153,154]. In
the absence of cracked or bleeding nipples, breastfeeding of prop-
erly immunized infants is encouraged (B2). Unlike interferon
(IFN), which is not excreted in breast milk, lamivudine andJournal of Hepatology 201tenofovir are excreted (although no data are available yet for ten-
ofovir in humans), but the dose adsorbed by the infants is negli-
gible compared to standard oral doses [155,156]. Nevertheless,
no systematic study has been conducted to evaluate the effects
of nucleos(t)ide analogues (NA) absorbed from maternal milk
on breastfed infants. Though there are data suggesting that
breastfeeding while on lamivudine and tenofovir is safe [156]
at present, breastfeeding cannot be recommended, and the risk
of potential long-term effects on the infant should be weighed
against the risk of stopping the antiviral therapy. Entecavir has
not been studied in pregnant women as yet, but was shown to
be excreted in breast milk in rats and to have carcinogenic poten-
tial both in mice and rats after placental transfer. No data are
available yet for telbivudine.
Natural history
Chronic hepatitis B, deﬁned as positivity for HBsAg for 6 months
or longer, is a mild disease in childhood [1]. Most infected chil-
dren are asymptomatic, with a normal growth and a normal
physical examination [35]. The great majority of perinatally
infected subjects are HBeAg-positive, with high serum levels of
HBV DNA and normal serum alanine aminotransferases (immu-
notolerant phase). Transplacental transfer of maternal HBeAg
has been suggested to elicit HBe/HBcAg-speciﬁc Th cell tolerance
in utero [157–160]. Such mechanism could explain the different
chronicity rates between neonatal and adult infection, as well
as the higher chronicity rate in babies born to HBeAg-positive
mothers, in whom high-level viral replication leading to large
amount of HBeAg would maintain the tolerance to HBV [56]. This
immunotolerant phase, which lasts 10–30 years, is usually
marked by high viral replication and little liver damage. Never-
theless, 1.7–4.5% of children and adolescents infected at birth
have cirrhosis at liver biopsy [35,36].
Over time, HBV DNA levels ﬂuctuate and ALT levels rise,
reﬂecting the histologic ﬁnding of necroinﬂammation of liver
parenchyma. This phase of active hepatitis leads to seroconver-
sion to anti-HBe antibodies in 60–95% of patients on long-term
follow-up [36,37]. ALT levels increase before HBeAg clearance
and may remain elevated (with ﬂare-ups in 20% of subjects) for
6–12 months after seroconversion [11,35,38,39]. Most HBsAg-
positive, HBeAg-negative, and anti-HBe-positive patients (i.e.
those who undergo HBeAg seroconversion) are deﬁned as inac-
tive carriers, have absent or low viral replication (HBV DNA
<2000 IU/ml) and usually inactive liver histology, with normal
ALT levels. Over a long-term follow-up (24–29 years), inactive
carriers with no signs of cirrhosis at seroconversion do not show
disease progression, whereas 1–5% of HBeAg-positive children
develop cirrhosis [2,35,36].
Although the incidence of HCC in high HBV prevalence areas
has been signiﬁcantly reduced by global immunization programs,
between 0.01% and 0.03% of children with CHB develop HCC dur-
ing childhood (32 per 100,000 person-year) [14,36,40,41]. Chil-
dren developing HCC are more likely to be males (70%), with
cirrhosis (80%), and to have undergone early seroconversion (sug-
gesting that necroinﬂammation during seroconversion to anti-
HBe may be severe enough to lead to cirrhosis and HCC)
[14,36,40]. In adult patients, the long-term risk of both HCC
and cirrhosis is directly correlated to serum HBV DNA levels
and HBeAg positivity [42–44]. No conclusion can be drawn from
pediatric studies because of the rarity of HCC during childhood
[36,40]. The role of viral genotype on the risk of developing3 vol. 59 j 814–829 815
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HCC is still to be clariﬁed in the pediatric population (80% of HCC
are in cirrhotic genotype B children, whereas in adults, genotypes
C and F are considered at increased risk) [14,45–48]. Further-
more, the risk of HCC is higher in individuals with a family his-
tory of HCC [4]. Seroconversion to anti-HBe reduces the risk of
developing HCC, but 0.2% of HBeAg-negative adults and 1.6% of
asymptomatic HBsAg carriers still develop HCC [49].
A subgroup of anti-HBe-positive subjects has active viral rep-
lication with abnormal ALT levels and histologically active hepa-
titis (HBeAg-negative chronic hepatitis). HBeAg-negative
hepatitis affects about 10% of pediatric patients, who show a
more severe disease progression and have a higher incidence of
HCC than HBeAg-negative patients in sustained remission [49].
Between 7% and 25% of inactive carriers lose HBsAg and
become anti-HBs-positive over a 20-year follow-up [50]. Unfortu-
nately, spontaneous seroconversion to anti-HBs is a rare event in
childhood (0.6–1%/year) [35,36,38]. Such an event marks resolu-
tion of HBV infection, and leads to an improved liver histology.
HBsAg seroclearance, if it occurs before the development of cir-
rhosis or HCC and in the absence of concomitant infections, has
an excellent long-term prognosis [51]. Nevertheless, covalently
closed circular DNA (cccDNA) persists indeﬁnitely in hepatocytes,
and low-level viral replication or reactivation upon immunosup-
pression is always possible. Moreover, the HBV genomemay inte-
grate in the host genome, increasing the risk of HCC development
even after HBsAg seroclearance [52,53].
As a reﬂection of the transcriptional activity of cccDNA, HBsAg
levels decreasewithage anddisease progression, beinghigher dur-
ing the immunotolerance phase, lower after seroconversion to
anti-HBe, and reaching the lowest levels in inactive carriers [161].Methods
These guidelines were developed by a panel of experts chosen by the European
Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). Rec-
ommendations were based on evidence from existing papers published before
June 2012 and, when evidence was not available, on experts’ personal experience.
Evidence has been evaluated by the authors and classiﬁed as high (A), moderate
(B), or low (C) quality according to the Grading of Recommendations Assessment
Development and Evaluation (GRADE) system [54–56]. The strength of recom-Table 1. Grading of evidence and recommendations according to the GRADE system
Grading of recommendation
Implications for clinicians
Strong recommendation warranted Most patients should receive the 
recommended course of action
Weaker recommendation Different choices will be appropria
different patients
Grading of evidence
High quality
lies close to that of the estimate o
Moderate quality
estimate: The true effect is likely 
to the estimate of the effect, but t
possibility that it is substantially d
Low quality
limited: The true effect may be su
different from the estimate of the 
Definition
We are very confident that the tru
We are moderately confident in th
Our confidence in the effect estim
816 Journal of Hepatology 201mendations (1: strong; 2: weak) reﬂects the extent to which we can be conﬁdent
that the desirable effects of the intervention outweigh the undesirable effects,
and is based on the balance between desirable and undesirable effects, the quality
of underlying evidence, variability in values and preferences and the costs of the
intervention (Table 1).End points of treatment and deﬁnitions of response
The goal of anti-HBV therapy, in children as in adults, is to
improve long-term survival and quality of life by reducing the
risk of progressive liver disease, cirrhosis, and HCC.
For all patients, the ideal end point of treatment is sustained
HBsAg clearance, as it stops disease progression and reduces
the risk of HCC, although it occurs in a minority of treated sub-
jects (A1) [51,57].
When HBsAg seroclearance is not achieved, sustained off-
therapy suppression of viral replication (undetectable HBV DNA
levels with a sensitive real time polymerase chain reaction assay),
associated with durable anti-HBe seroconversion in originally
HBeAg-positive patients, is a good end point, being associated
with improved prognosis, including decreased risk of HCC (A1)
[44]. In the absence of off-therapy viral suppression, undetectable
HBV DNA under long-term antiviral therapy (maintained virolog-
ical response) is the next desirable end point (A1). Reduction of
viremia levels leads to decreased liver inﬂammation and subse-
quent normalization of ALT levels, reducing the risk of disease
progression [2,35,36,42,43].
Response to treatment can be evaluated at biochemical, sero-
logical, virological andhistological levels. In the fewavailable pedi-
atric trials, several end points have beenused to evaluate response.
A consensus on the deﬁnition of response would be required to
compare the different clinical trials. Current AASLD and EASL def-
initions can be adapted to pediatric clinical trials [6,8]:
 Biochemical response: normalization of ALT levels, which
reﬂects reduction of histological activity index. ALT level
is, however, a difﬁcult parameter to assess because it can
ﬂuctuate widely over time and can remain elevated up to
6–12 months after HBeAg seroconversion. ALT levels,[54].
Implications for patients Symbol
Most informed patients would choose the 
recommended management
1
te for Patients’ choices will vary according to their 
values and preferences
2
Type of evidence Symbol
f the effect
Randomized controlled trials A
to be close 
here is a 
ifferent
Randomized controlled trials with risk of 
bias, high quality observational studies 
B
bstantially 
effect
Observational studies, case reports, 
experts’ opinion
C
e effect
e effect
ate is
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Yes
Yes
No
No
Children with CHB
Normal ALT Persistently elevated ALT Decompensated liver disease
HBeAg+ HBeAg+HBeAg- HBeAg-
HBV DNA 
>20,000 IU/ml
HBV DNA 
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Immunotolerant 
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Immunoactive
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Exclude other 
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Fig. 1. Treatment algorithm for pediatric patients with CHB (modiﬁed from [1]). ⁄Recommendation valid until results of ongoing trials on the treatment of
immunotolerant children are available. ⁄⁄It is likely that PegIFN will replace IFN-a as the ﬁrst-line treatment for CHB once the results of ongoing clinical trials are available.
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ﬁrst year post-treatment (C1) and every 6 months during
the second year post-treatment (C2).
 Serological response for HBeAg is deﬁned as HBeAg loss
and seroconversion to anti-HBe (only for HBeAg-positive
patients); serological response for HBsAg is deﬁned as loss
of HBsAg and development of anti-HBs antibodies (valid for
all chronic hepatitis B patients).
 Virological response (VR): undetectable levels of HBV DNA
(as determined by a sensible PCR assay) after 3–6 months
of treatment for NA-treated patients or HBV DNA
<2000 IU/ml after 6 months and at the end of treatment
for IFN-treated patients.Journal of Hepatology 201 Complete response: off-treatment virological response
associated with HBsAg loss sustained on long-term fol-
low-up.
 Sustained off-treatment virological response (SVR): VR per-
sisting at least 12 months after cessation of treatment.
 Maintained virological response: undetectable HBV DNA
under long-term antiviral therapy.
 Partial virological response: decrease in HBV DNA of more
than 1 log10 IU/ml but detectable HBV DNA after at least
6 months of treatment with NA.
 Primary non-response: less than 1 log10 IU/ml decrease
in HBV DNA levels from baseline after 3 months of
therapy.3 vol. 59 j 814–829 817
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 Virologic breakthrough: HBV DNA level increase of more
than 1 log10 IU/ml during therapy, usually caused by poor
adherence to treatment or emergence of a drug-resistant
HBV mutant.
 Histologic assessment of necroinﬂammatory activity has
not been used as a criterion to evaluate response to treat-
ment in pediatric studies.Who and when to treat
Decision to treat must take into account the mild evolution of the
disease during childhood, the risk of disease progression later in
life, the development of severe complications in few, not yet well
identiﬁed children, the efﬁcacy of current antivirals, their side
effects, and the limited number of drugs labeled for use in this
age group. A treatment algorithm is proposed in Fig. 1.
The need for treatment should be evaluated at each follow-up
visit, in order to initiate antiviral drugs at the earliest signs of
liver damage (C2). Children with CHB should undergo physical
examination and measurement of serum ALT and HBeAg/anti-
HBe levels every 6 months (C1). In HBeAg-positive patients with
persistently elevated ALT, their levels should be monitored every
3 months for at least one year (B1). In HBeAg-negative patients,
ALT and HBV DNA levels should be measured 4-monthly within
the ﬁrst year to rule out HBeAg-negative hepatitis. After conﬁr-
mation of the inactive carrier status (normal ALT and HBV DNA
<2000 IU/ml), patients should be monitored every 6 months
(B1). Full blood count and liver function tests should be per-
formed yearly (C1). HCC surveillance with liver ultrasound
should be done every 6–12 months, depending on the stage of
ﬁbrosis [190]. Alpha-fetoprotein (AFP), although widely used,
was recently shown to provide insufﬁcient sensitivity and speci-
ﬁcity for effective surveillance [191,192]. Lifetime follow-up is
warranted even for inactive carriers, because of the risk of cirrho-
sis, HCC and reactivation of HBV infection, with seroreversion to
HBeAg-positive status or progression to HBeAg-negative hepatitis
(C1) [49,58].
Currently, decision to start treatment is based on ALT levels
(which reﬂect ongoing liver damage), HBeAg positivity, HBV
DNA levels, liver histology, family history of HCC, co-existing liver
diseases and patient’s treatment history.
As the upper limit of normal (ULN) for ALT levels in pediatric
age has not been established yet, it is advised that a patient
should be considered for antiviral treatment if ALT levels are
more than 1.5 times the laboratory ULN or more than 60 IU/L
(value used as inclusion criterion in the three largest trials in chil-
dren [59–61]), whichever is lower (C2) [9]. Patients with lower
transaminases have fewer chances to achieve serological
response [59,60]. A lower threshold based on larger pediatric
cohorts may be used in future studies to avoid underestimation
of liver damage, but this approach may reduce the overall rate
of serological response and increase the need of prolonged treat-
ment of patients with maintained VR under antiviral drugs [62].
Antivirals should be considered for children with elevated
serum ALT levels for at least 6 months (12 months if HBeAg-neg-
ative), in order to avoid treating patients who are undergoing
spontaneous HBeAg seroconversion (C1).
In the presence of high ALT levels, assessment of serum HBV
DNA levels is important, as high HBV DNA values warrant antivi-
ral treatment, whereas low levels should instigate investigations818 Journal of Hepatology 201to exclude other causes of liver disease. The cut-off value for HBV
DNA, however, has not been deﬁned for children. As young
patients have a higher HBV replication rate than adults, a value
of 20,000 IU/ml has been chosen by different authors [7,63].
However, lower values have been associated with progressive
liver disease in adults, and latest management guidelines for
adult patients identiﬁed 2000 IU/ml to be a more reliable cut-
off [6,8]. Such a cut-off appears to be appropriate for children
as well (C1).
In patients older than 40 years of age, antiviral treatment is
advocated in the presence of a high viral load in isolation, as this
is an independent risk factor for cirrhosis and HCC [42,43]. No
data exist in children to support such an approach. Therefore,
as response to currently available antivirals in children is partial
and limited to speciﬁc subgroups, histologic assessment of the
degree of inﬂammation and of the stage of ﬁbrosis is recom-
mended before considering treatment (A1). Response to both
interferon(IFN)-a and NA is more likely when at least moderate
necroinﬂammation or moderate ﬁbrosis is found at liver histol-
ogy (A1) [59,64]. Although the beneﬁt of treatment has not been
established for children with mild inﬂammation or ﬁbrosis, a
family history of HCC may warrant treatment even in children
with mild histological changes, as they are at increased risk of
developing HCC (B2) [4].
Although still not fully validated, non-invasive methods to
assess the degree of hepatic ﬁbrosis, such as FibroScan, could
prove useful to avoid liver biopsy, especially during follow-up
[8,162–165]. However, no sufﬁcient data are available in children
and, at present, these non-invasive methods cannot substitute for
liver biopsy in the decision to treat a child or an adolescent with
chronic hepatitis B, as these methods evaluate more ﬁbrosis than
necroinﬂammatory activity (C2).
Antiviral treatment with NA should be instituted in HBV
infected children undergoing liver transplantation or in recipients
of grafts from anti-HBc-positive donors to prevent (or treat)
recurrent HBV infection (C1). Prophylactic anti-HBV therapy
should also be administered to HBsAg-positive patients who are
going to receive immunosuppressive or cytotoxic treatment, as
it decreases the risk of mortality and morbidity related to HBV
reactivation (B1) [65]. Children with cirrhosis, HBV-related glo-
merulonephritis, or co-infection with HDV, HCV or HIV are at
increased risk for a rapid progression of liver disease. These
patients might beneﬁt from treatment even if ALT, HBV DNA lev-
els, and liver histology do not match the criteria listed above (C2).
If antiviral treatments were able to achieve complete viral
control (i.e., anti-HBs seroconversion), the ideal children to treat
would be those tolerant to HBV, in order to obtain the production
of neutralizing antibodies before the onset of complications.
These children, who have normal or mildly elevated ALT levels
and a high viral load, have been shown not to respond to isolated
interferon treatment [59,60,66–68] and are not good candidates
for current NA therapy because of the risk of developing antiviral
resistance [69]. A pilot open study in small cohort of tolerant chil-
dren has shown promising results with a combined protocol, in
which 8 weeks of lamivudine treatment to decrease the viral load
were followed by 44 weeks of combined lamivudine and IFN-a
treatment [70]. On the basis of this study, two controlled trials
in tolerant children are currently being conducted in the UK
(lamivudine/pegylated IFN-a) and in the USA (entecavir/
pegylated IFN-a) [71,72]. Until the results of these studies
become available, children in the immunotolerant phase should3 vol. 59 j 814–829
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not be treated, but should be monitored, and treated only if an
increase of ALT levels reveals immune activation (A1).%
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Fig. 2. Response to antiviral treatments currently licensed for children: rates
of virological (white bars), serological (HBeAg loss: light blue bars; HBeAg
seroconversion: blue bars; HBsAg loss: dark blue bars) and biochemical (black
bars) response in pediatric clinical trials. Entecavir has not been included as no
pediatric trials have been conducted so far.Efﬁcacy of currently available therapies
The U.S. Food and Drug Administration (FDA) approved ﬁve med-
ications for treatment of children with CHB: IFN-a, lamivudine,
adefovir, entecavir and, recently, tenofovir. IFN-a can be used
in children older than 12 months of age, lamivudine starting at
3 years of age, adefovir and tenofovir in children aged 12 years
and older, and entecavir starting from 16 years of age. Each of
these treatments has advantages and disadvantages (Table 2).
Response rates and side effects are summarized in Fig. 2 and
Table 3. So far, none of these medications have been approved
by the European Medical Agency for the treatment of children.Predictors of response
Several baseline and on-treatment predictors of response have
been identiﬁed for children treated with IFN-a and lamivudine,
whereas no data from pediatric studies exists for other NA.
In HBeAg-positive patients, likelihood of response to IFN-a is
associated with low HBV DNA levels and elevated ALT levels
(more than twice the ULN) before treatment, younger age and
female sex (A1) [59,91–93]. Elevated ALT levels at baseline areTable 2. Available treatments for chronic hepatitis B in pediatric age.
Treatment Licensing Dose Duration A
IFN-α ≥12 mo 5-10 M units/m2 sc 
three times weekly
6 mo •
•
•
Lamivudine ≥3 yr 3 mg/kg po once daily 
(max 100 mg/die)
≥1 yr •
•
•
Adefovir ≥12 yr 10 mg po once daily ≥1 yr (+ 6 mo 
after HBeAg 
seroconversion)
•
•
Entecavir ≥16 yr + 
phase III 
(2-17 yr)
0.5 mg po once 
daily (1 mg/day for 
lamivudine-resistant 
pts)
≥1 yr (+ 6 mo 
after HBeAg 
seroconversion)
•
•
Tenofovir ≥12 yr 300 mg po once daily ≥1 yr •
•
•
•
•
PegIFNα Phase III 
(2-18 yr)
180 µg/wk 6 mo •
•
•
Telbivudine Phase I 
(2-18 yr)
600 mg po once daily ≥1 yr •
•
•
Journal of Hepatology 201associated with higher long-term seroconversion rate after treat-
ment (B2) [74]. Early response to IFN-a is more likely to lead to
HBsAg loss than late or no-response (C2) [73]. A better response
to IFN-a has been shown in adults for viral genotypes A and B,
compared to D and C [15,94–96]. No pediatric studies have yet
investigated the role of genotype on response to antiviral
therapy, and genotype determination before treatment is not
currently recommended (C2), until the role of the viral genotypedvantages Disadvantages
 No resistance
 Licensed for young children
 Short treatment
• Side effects
• Parenteral administration
• Not usable if decompensated 
cirrhosis or transplantation
 Few side effects
 Oral administration
 Usable in 3rd trimester of 
pregnancy
• High resistance rate (increasing 
with time of treatment)
 Partially effective in 
lamivudine resistant 
patients
 Oral administration
• Not approved for children <12 yr
• High resistance rate (increasing 
with time of treatment)
 Low resistance rate
 Oral administration
• Not approved for children <16 yr
 High response rate
 
 Few side effects
 Oral administration
 Usable in 3rd trimester of 
pregnancy
• Not approved for children <12 yr
• Reduced mineral density in 
children
 No resistance
 Once weekly administration
 Short treatment
• Side effects
• Parenteral administration
• Not usable if decompensated 
cirrhosis or transplantation
 Few side effects
 Oral administration
 Usable in 3rd trimester of 
pregnancy
• High resistance rate
No resistance identified
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Table 3. Efﬁcacy and safety of treatments for chronic hepatitis B [82,83,86,188]. (See below-mentioned references for further information.)
Treatment Study P/A Type Patients 
(N treat./cont.)-duration
VR
% treat/cont 
(p value)
Serological response
% HBe loss/HBe SC/HBs loss
Resist. 
%
HR
% treat/cont 
(p value)
More frequent side effects  
(% treat./cont.)
Treat Cont p value
IFN-α Sokal 1998 
[60]
P OL RCT
(vs. PLB)
HBeAg+, ALT >1.5x (70/74)-24 
wk
26/11 
(0.029)
72/-/10 -/-/1 -/-/0.03 - Flu-like symptoms (100/0), behavioral 
disorders (40/4), nausea/vomiting 
(40/8), diarrhea (46/16), neutropenia 
(19/5), alopecia (17/0)
Wong 1993 
[112]
A Meta-
analysis
HBeAg+ (498/339) 37/17 
(-)
33/-/8 12/-/2 0.0001/-/0.001 - Flu-like symptoms, leukopenia and 
thrombocytopenia, depression, 
alopecia. Dose reduction in 20%, 
termination in 5%
PegIFNα Lau 2005 
[103]
A PDB RCT
(vs. Lam)
HBeAg+, ALT >1x (271/272)-
48 wk
25/40 
(-)
30/27/3 22/20/0 - - I 49/51 
(-)
Pyrexia (49/4), fatigue (40/14), 
headache (28/10), myalgia (26/3), 
alopecia (20/2), anorexia (15/2), 
pruritus (10/2), arthralgia (9/3), 
depression (5/1), ALT elevation, 
neutropenia, thrombocytopenia
Janssen 2005 
[104]
A DB RCT 
(vs. 
PegIFN + 
Lam)
HBeAg+, ALT >2x (118/114)-
52 wk
10/33 
(<0.0001)
29/22/5 44/25/7 0.01/0.52/0.54 - I 22/33 
(-)
Flu-like symptoms (62/74), fatigue 
(43/42), headache (40/45), myalgia 
(30/32), alopecia (19/27), anorexia 
(16/16), arthralgia (16/15), depression 
(21/22), neutropenia (21/26), 
thrombocytopenia (13/11)
Lamivudine Jonas 2002 
[61]
P DB RCT
(vs. PLB)
HBeAg+, ALT >1.3x (191/95)-
52 wk
23/13 
(0.04)
26/22/2 15/13/0 0.03/0.06/- 19 Adverse events similar between 
treated and untreated children
Sokal 2006 
[81]
P OL
extension
HBeAg+, ALT >1.3x, Lam 52 wk 
(134)-36 mo
28/- -/25/2 - - 64 ENT infections (37), headache (19), 
abdominal pain (14), nausea/vomiting 
(13), ALT increase (3)
Dienstag 1999 
[210]
A DB RCT
(vs. PLB)
HBeAg+, ALT >1.3x (66/71)-
52 wk
44/16 
(<0.001)
32/17/2 11/6/0 0.003/0.04/- 32 Malaise/fatigue (19/20), nausea/
vomiting (9/15), headache (9/8), 
abdominal discomfort (4/7), rash (6/8), 
diarrhea (6/6)
Adefovir 
dipivoxil
Jonas 2008 
[62]
P DB RCT
(vs. PLB)
HBeAg+, ALT >1.5x (115/58)-
48 wk
11/2 
(-)
17/16/- 5/5/- -/0.051/- 0 Mild CK increase (22/26), mild 
creatinine increase (16/11), severe 
Jonas 2012
[89]
P OL
extension
HBeAg+, ADV 52 wk (108)-
240 wk
35/- - - - 0.9
disorders (2), growth retardation
Marcellin 2003 
[120]
A DB RCT
(vs. PLB)
HBeAg+, ALT >1.2x (172/170)-
48 wk
21/0 
(<0.001)
24/12/- 11/6/- <0.001/0.049/- 0 Flu-like symptoms (16/19), headache 
(25/22), abdominal pain (18/19), 
nausea (10/14), diarrhea (13/8), ALT 
increase >10x (10/19)
Marcellin 2008 
[90]
A OL
extension
HBeAg+, ADV 2 yr (171)-240 wk 39/- 58/48/2 - - 20 Asthenia (18), headache (14), 
abdominal pain (11), anorexia 
(6), nausea (6), diarrhea (6), ALT 
increased (18), creatinine increase (8) 
hepatic flare (3/0)
Severe hepatic flare (3), mood
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Entecavir Chang 2006 
[91]
A DB RCT
(vs. Lam)
HBeAg+, ALT >1.3x (354/355)-
48 wk
67/36 
(<0.001)
22/21/2 20/18/1 0.45/0.33/0.52 0 K 72/62 
(0.009) 
I 7/-
ALT elevation (10/17), post-treatment 
Chang 2010 
[197]
A OL 
extension
HBeAg+, ALT >1.3x (94)-
240 wk
94/- 31/-/5 - - 0.7 - Upper respiratory tract infections 
(31), headache (21), diarrhea (16), 
increased ALT (1), liver abscess (1)
Chang 2010 
[198]
A OL 
extension
HBeAg+/-, ALT >1.3x (57)-6 yr 100/- 55/33/0 - - 1.2 K 96/-
I 58/-
-
Tenofovir 
disoproxil 
fumarate
Murray 2012 
[99]
P DB RCT
(vs. PLB)
HBeAg+/-, ALT >2x (51/50)-
72 wk
89/0
(<0.001)
21/-/2 15/-/0 n.s./-/n.s. 0 - Headache (4/15), upper respiratory 
tract infections (10/13), acne (19/4), 
abdominal pain (6/13), ALT increase 
(6/22), >4% decreased BMD (6/4)
Marcellin 2008 
[97]
A DB RCT
(vs. ADV)
HBeAg+, ALT >2x, 12-18 yr, 
(176/90)-48 wk
76/13 
(<0.001)
-/21/3 -/18/0 -/0.36/0.02 0 K 78/71 
(n.s.)
Headache (13/14), nasopharyngitis 
(10/11), nausea (9/3), fatigue (8/7), 
increase (3/1), creatinine elevation 
(0/1)
Marcellin 2013 
[196]
A OL 
extension
HBeAg+, TDF 48 wk, (266)-
240 wk
65/-b 49/40/10 - - - I 98/- Serious adverse events (2%: ALT 
increase, osteoporosis, osteopenia, 
mild renal falure, acute pancreatitis, 
LDH increase), creatinine increase (1)
Gordon 2013 
[195]
A OL 
extension
HBeAg+/-, TDF 48 wk, (489)-
240 wk
98/-a 55/45/10 - - 0 -
Telbivudine Liaw 2009 
[108]
A DB RCT
(vs. Lam)
HBeAg+, ALT >1.3x (458/463)-
104 wk
56/39 
(<0.001)
35/30/1 29/25/1 0.06/0.1/0.99 25 - CK elevation (13/4), ALT elevation 
respiratory tract infections (18/16), 
fatigue (13/12), headache (12/13), 
diarrhea (7/6)
Wursthorn 
2010 [126]
A OL 
extension
HBeAg+, ALT >1.3 (205)-3 yr - 71/57/6 - - - -
Treatment Study P/A Type Patients 
(N treat./cont.)-duration
VR
% treat/cont 
(p value)
Serological response
% HBe loss/HBe SC/HBs loss
Resist. 
%
HR
% treat/cont 
(p value)
More frequent side effects  
(% treat./cont.)
Treat Cont p value
flare (2/12)
abdominal pain (10), ALT flare (0.7),
diarrhea (7/5), ALT flare (1/2), ALT
(6/12), ALT flares (2/5), upper
Table 3 reports studies on HBeAg-positive chronic hepatitis as, in children and adolescents, it is much more common than HBeAg-negative hepatitis.P, ped tric study; A, adults study; VR, virological response; SC,
seroconversion; DB, double-blind; PDB, partially double-blind; OL, open-label; RCT, randomized controlled trial; HR, histologic response [reduction of 2 or mo points in the Knodell necroinﬂammatory score (K), with no
worsening in the ﬁbrosis score, or in the Ishak ﬁbrosis score (I) at the end of the study protocol, as compared to baseline], n.s., not signiﬁcant.
aOn-treatment analysis.
bIntention-to-treat analysis.
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in assigning children to treatment and in predicting response has
been clariﬁed. A decrease of the HBsAg serum levels after the ﬁrst
3 months of treatment predicts SVR and HBsAg loss in adults
treated with pegylated IFN (PegIFN), but no data are available
in children treated with IFN-a [97–99].
The likelihood to respond to lamivudine is greater in children
with higher ALT levels (at least twice the ULN), and high histo-
logic activity index at baseline (A1) [60,75]. In adult patients,
the same parameters, as well as low HBV DNA levels (HBV DNA
<2  108 IU/ml), were predictive of response to all NA (A1)
[85,90,100,101]. No signiﬁcant difference in response to NA was
found among different genotypes (A1) [102,103]. In adults, VR
at 24 weeks during treatment with lamivudine or telbivudine
(and 48 weeks during treatment with adefovir) is associated with
a higher chance of HBeAg seroconversion, maintained virological
response, and lower incidence of resistance (B1) [90,104–106].
The decline of HBsAg serum levels during NA treatment predicts
HBeAg seroconversion or HBsAg loss (C2) [107–109].Treatment strategy
Currently, a ﬁnite-duration IFN-a therapy remains the treat-
ment strategy of choice for HBeAg-positive children with ele-
vated ALT levels (A1), as in this patient population
seroconversion to anti-HBs is the main aim. IFN-a is the only
available treatment offering a chance of sustained off-treatment
VR. It is likely that, as soon as results of trials using PegIFN in
children [89] are available, this medication will become the rec-
ommended drug. Although adverse effects may be serious and a
clear beneﬁt on the long-term remains to be conﬁrmed, the use
of IFN-a is not associated with the emergence of genotypic
resistance. The recommended regimen is 5–10 million units
per square meter, three times weekly for 6 months (A1). For
PegIFN, studies in adults show the highest HBeAg seroconver-
sion rate with 48-week treatment schedules [166] (A1). IFN-a
is contraindicated in children with decompensated cirrhosis,
cytopenia, autoimmune disorders, cardiac or renal failure, and
in transplanted patients (B1) [68]. The possible beneﬁt of prim-
ing with corticosteroids has not been proven (C2) [110–112].
On-treatment response was higher with the combination of
IFN-a and lamivudine than with IFN-a alone, both in adults
and in children, but no beneﬁt was seen for off-treatment
response rate [76–80,87,88,167]. Thus, the combination is cur-
rently not recommended (C2). Furthermore, in adults combined
IFN-a and telbivudine treatment has been reported to be asso-
ciated with polyneuropathy (A1) [168]. IFN-a is the only treat-
ment licensed for treating children younger than 3 years of age,
who however rarely require therapy (A1). In this age group, the
risk of IFN-related neurotoxicity (although mostly minor and
transient) has to be taken into account [59,113]. In case of no
response, at least 6–12 months should elapse before considering
other therapies, as VR may be achieved during the 6 months fol-
lowing the end of IFN-a treatment (B1).
NA used to be second-line therapies because of the high risk of
emergence of resistant mutant strains. Nevertheless, the recent
FDA approval of NA with higher genotypic barrier to resistance
has opened the way for the use of such drugs as ﬁrst-line treat-
ment for adolescents. In patients older than 12 years of age, ten-
ofovir (or entecavir for patientsP16 years old) is the best choice,
as response rate is high and resistance is less likely (A1). The822 Journal of Hepatology 201recommended dose for tenofovir is 300 mg once daily, and for
entecavir is 0.5 mg once daily (for nucleoside-naïve patients)
(A1). Although not yet approved for the treatment of CHB in
patients <12 years of age, the use of tenofovir might be safe in
younger children, as it is already widely used (and FDA-licensed)
for patients older than 2 years of age with HIV infection. A phase
3 clinical trial in 2–11-year-old CHB patients is currently under-
way [189]. Since the approval of tenofovir for adolescents, adefo-
vir is no more recommended because of the higher risk of
resistance and the lower response rate (B1) [61,81].
A ﬁnite-duration treatment with tenofovir or entecavir is pos-
sible if seroconversion to anti-HBe is achieved on treatment (C2).
Duration of treatments with NA has not been established, but
they should be continued for at least 12 months after reaching
undetectable HBV DNA levels and HBeAg seroconversion (B1)
[8,169]. As an important proportion of adult patients was shown
not to maintain their serological and virological response, treat-
ment up to HBsAg clearance could be a safer choice for patients
with histological evidence of severe ﬁbrosis (C2) [170]. Patients
should be monitored after discontinuation because of the possi-
bility of post-treatment ﬂares (B1).
Patients who do not undergo HBeAg seroconversion on treat-
ment, the rare children with HBeAg-negative chronic hepatitis
and cirrhotic patients need long-term treatment with NA (B1).
Tenofovir or entecavir, if allowed by the age, are the ﬁrst choice
(A1). Long-term efﬁcacy and safety data in adults support such
a strategy, but no data are available for adolescents as yet
[173–176]. During long-term treatment with NA, HBV DNA levels
should be monitored every 3 months, as HBV DNA reduction to
undetectable level is of paramount importance to avoid resis-
tance (B1).
Although guidelines in adults do not recommend the use of
lamivudine monotherapy [6,8], the risk of the emergence of resis-
tant strains has to be balanced against the fact that lamivudine is
the only NA currently approved for younger children. Its use
should be limited to the rare young children unresponsive to
IFN-a and requiring immediate treatment and to special popula-
tions (see below) (C1). The recommended treatment dose for
lamivudine is 3 mg/kg/day (maximum 100 mg/day), adminis-
tered orally once daily (A1) [114]. Optimal treatment duration
is more difﬁcult to determine. Treatment should be continued
until VR is achieved, and possibly for 12 months after seroconver-
sion (B1) [75,169]. As longer treatment duration leads to higher
resistance rates, it is recommended to discontinue lamivudine
after 6 months if a complete suppression of viral replication is
not achieved or if resistant mutations emerge (B1). As post-treat-
ment ALT ﬂares are possible, children should be carefully moni-
tored and a reinstitution of lamivudine treatment (in patients
who have not developed resistance) or an alternative therapy
(tenofovir if possible for the age) should be started in the rare
cases with severe and protracted ALT elevation (A1) [115]. For
children with cirrhosis, who need antiviral treatment to be con-
tinued, switch to tenofovir (ifP12 years of age), alone or in com-
bination with entecavir (if P16 years of age) or maintenance of
lamivudine (if <12 years of age) despite an incomplete VR is rec-
ommended (C2) [171,172]. Combination therapy with IFN-a and
lamivudine is promising, but further data are needed in children
(C2). Combination therapy with adefovir and lamivudine has
been tried only in children not responding to adefovir mono-
therapy, and its efﬁcacy has not been compared to monotherapy
[81].3 vol. 59 j 814–829
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Although no data are available from pediatric studies, current
guidelines in adults suggest that, for HBeAg-negative patients
who have persistently elevated ALT values (at least 3 measure-
ments in 12 months) and high HBV DNA levels, the same treat-
ment algorithm applied to HBeAg-positive children should be
considered (C1) [6,8]. Nevertheless, attention should be paid to
the higher relapse rate and the longer duration of treatment
needed [116–118].Treatment failure and antiviral resistance
Partial response to NA or primary non-response is often due to
the emergence of genotypic resistant strains or to patient non-
adherence to treatment. In non-responders, HBV genotypic anal-
ysis is warranted in order to differentiate between resistance and
patient non-compliance (C1). Non-compliance may be a major
issue in adolescents, especially if long-term treatment is required
to maintain response.
In responders, virologic breakthrough (which may be fol-
lowed by biochemical breakthrough) is usually secondary to
genotypic resistance. Likelihood of virologic breakthrough
depends on the intrinsic barrier to resistance of the speciﬁc
NA (lamivudine >telbivudine >adefovir >entecavir >tenofovir).
All children receiving NA should be monitored for virologic
breakthrough by measuring HBV DNA levels every 3 months
(C1). Ideally, identiﬁcation of virologic breakthrough and conse-
quent adaptation of treatment should be performed as early as
possible, before ALT levels rise [6,69]. Because of the low num-
ber of effective drugs approved, when resistance to an NA devel-
ops in children, the decision on therapy adjustment is based on
liver biopsy and the patient’s age. If mild hepatitis is present,
he/she should be switched to either entecavir (for adefovir-
resistant, P16 years old and lamivudine-naïve patients) or ten-
ofovir (for P12 years old, lamivudine-resistant patients or ade-
fovir-resistant patients previously treated with lamivudine)
(C2). For younger children, for whom no other NA other than
lamivudine is approved at the moment, switching to IFN-a (Peg-
IFN when approved) can be a possibility (C2). Treatment with
lamivudine should be stopped and the child should be followed
up in the eventuality of post-treatment ﬂares (C2). In case of
moderate hepatitis/ﬁbrosis, the patient should be switched to
tenofovir if P12 years old, or, if younger, to IFN-a (C2). If severe
hepatitis is found at liver biopsy, switching to tenofovir is the
only available choice (as monotherapy or associated to entecavir
if the child is P16 years old and has high viral load) (C2)
[171,172]. Both tenofovir and entecavir are effective in lamivu-
dine-resistant patients [69], but an increased resistance rate has
been observed for entecavir (8% after 2-year treatment) and
higher dose (1 mg daily) is required (B1) [84,119]. Lamivudine
should therefore be discontinued when switching to entecavir
to decrease the risk of emergence of resistant mutants (C2)
[6]. Tenofovir can be used in lamivudine-resistant mutant
strains, as their activity is not hampered by such mutations
(B1) [69,81].
In patients with partial virological response at week 24 (for
those receiving lamivudine) or 48 (for those receiving adefovir),
switch to tenofovir or entecavir (if allowed by the age) is recom-
mended (B1). The strategy for children younger than 12 years of
age is difﬁcult to deﬁne. Patients could be switched to IFN-a
(or PegIFN) if not tried yet (C1), or lamivudine could be eitherJournal of Hepatology 201continued up to the 12th birthday (the only choice in those with
severe ﬁbrosis or cirrhosis) or stopped (with proper post-treat-
ment follow-up) (C2).
As the emergence of resistant mutant strains is becoming a
major public health problem, pediatric practitioners should not
treat children who are not likely to beneﬁt from a licensed ther-
apy and consider waiting for market approval of more effective
drugs (C1).Special populations
Treatment strategies for special populations of HBV infected chil-
dren are rarely based on strong evidence. Indications and type of
treatment are decided on the basis of few available case reports
and are often extrapolated from evidence obtained in adult
patients. Such children should be referred to specialized tertiary
centers where individualized treatments (even with off-label
newer antivirals) can be administered.
Immunocompromised children
All children candidate for chemotherapy or immunosuppressive
therapy should be screened for HBsAg, anti-HBs, and anti-HBc,
and seronegative patients should be vaccinated (A1). Prophylac-
tic treatment with NA should be considered for inactive carriers
requiring immunosuppressive therapy (transplanted patients,
patients undergoing cytotoxic chemotherapy, corticosteroids
treatment, rituximab, anti-TNF-a or other monoclonal antibody
therapies), in order to prevent reactivation (A1) [6,120]. NA treat-
ment should be continued for 12 months after cessation of the
immunosuppressive therapy (C1). NA with high genetic barriers
to resistance should be used for patients with CHB and for inac-
tive carriers requiring long or repeated cycles of immunosuppres-
sive therapy (C1). Lamivudine could be sufﬁcient for children
with low viral load or requiring a short duration of immunosup-
pression (C2). HBsAg-negative, anti-HBc-positive children (prior
infection) should be treated as HBsAg-positive subjects if they
have detectable HBV DNA (C2). If they have undetectable HBV
DNA levels, they should be followed and treated upon reactiva-
tion of HBV infection (C2). Prophylaxis with lamivudine should
be administered to HBsAg-negative, anti-HBc-positive children
receiving rituximab or combined regimens for hematological
malignancies or undergoing bone marrow or stem cell transplan-
tation (C1) [177–181].
Organ transplantation
If the recipient has been successfully immunized before surgery,
the risk of HBV infection after transplantation of non-hepatic
solid organs from HBsAg-negative, anti-HBc-positive donors
(i.e., with past HBV infection) is low, despite immunosuppression
[121]. The risk of infection is higher after liver transplantation
from anti-HBc-positive donors, with a 10% rate of de novo hepa-
titis in successfully vaccinated recipients and 69% recurrence rate
in HBsAg-positive recipients [122–124]. Presence of anti-HBs
antibodies per se does not guarantee protection against de novo
HBV infection, whereas the achievement of a high anti-HBs titer
(>200 mIU/ml) is protective [125]. Therefore, immunization (with
the achievement of an adequate anti-HBs titer) and prophylaxis
with lamivudine, tenofovir or entecavir (according to patient’s3 vol. 59 j 814–829 823
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age) for an indeﬁnite period of time, and HBIG are recommended
when transplanting an anti-HBc-positive liver to an HBV naïve
recipient (C1) [126]. Anyway, because of the long post-transplant
life expectancy, HBc-positive liver grafts should be discarded
when transplanting pediatric patients (C2).Co-infection with HIV, HCV or HDV
HIV infection should be ruled out in children from high-preva-
lence countries, as well as in adolescents who are injection drugs
users. HBV/HIV-co-infected patients are at increased risk of dis-
ease progression [127]. Furthermore, they are at increased risk
of developing resistance against lamivudine if used as mono-
therapy [128]. Because of the risk of inducing HIV resistance, ent-
ecavir should only be used in patients receiving effective
antiretroviral therapy [129] (A1). In HBV/HIV-co-infected adult
patients, the combination of tenofovir (approved for HIV-infected
children P2 years old) and emtricitabine or lamivudine is the
recommended treatment (A1). Tenofovir monotherapy should
not be administered to co-infected patients because of the risk
of HIV resistance (A1). Until stronger pediatric evidence is avail-
able, such recommendations may be extrapolated to co-infected
children (C2) [130,131]. The indications for therapy are the same
as in HIV-negative patients. According to HHS pediatric guide-
lines, no HIV treatment is required if the CD4 count is
P500 cells/mm3 in children P5 years of age (P750 if aged 3 to
<5 years and P1000 if aged 1 to <3 years) [182]. In these cases,
HBV may be treated before the institution of an anti-HIV therapy
with drugs inactive against HIV (such as IFN-a or PegIFN) (C2).
HBV/HCV co-infection is rare, and few data are available. IFN-
a (at doses recommended for HBV treatment) and ribavirin may
be a good option (C2). HBV/HDV co-infected children have more
severe liver disease than those with HBV alone. IFN-a is also the
drug of choice for these patients, although the only pediatric
study available has shown a transient effect with no therapeutic
beneﬁt in the long-term (24 months) compared to medium-term
(12 months) treatment (C2) [132,133].Table 4. Unsolved issues in the management of pediatric CHB.
• A better  of children at higher risk for disease progressi
increasing the risk of antiviral resistance
• Response to treatment of immunotolerant patients needs further att
population responds to currently available or newer antiviral treatme
• More clinical trials should be conducted to understand the role of ag
patients respond better than older ones)
• The relationship between HBV genotype and response to therapy n
• Pediatric licensing of newer drugs that are already the standard of c
is highly promising, and its licensing for children will probably chang
• Indications for treating children with nucleos(t)ide analogues need t
• Optimal duration of treatment with nucleos(t)ide analogues is still a 
balance between the advantages of viral suppression and the risk o
patients
• Children are still mostly treated with monotherapy. Possible advanta
trials
• Management of non-response, of antiviral resistance and of special
evidence extrapolated from adult studies. In view of the small numb
are needed to assess different treatment strategies
identification
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Acute symptomatic infection is rare in pediatric age, and it can
vary from a mild to a fulminant hepatitis. Classic symptoms are
present in 30–50% of older children and adolescents with acute
hepatitis B and include fever, jaundice, nausea and vomiting,
abdominal pain, liver tenderness, and fatigue, which last approx-
imately 2–3 months. Less than 10% of infants born to HBeAg-
positive mothers develop acute hepatitis, and jaundice may be
the only sign [183,184]. Fulminant hepatitis is uncommon in
infants and children but it is associated with a more than 40%
mortality rate without liver transplantation [185,186]. Therefore,
patients with fulminant hepatitis must be evaluated for liver
transplantation (A1). Such patients may beneﬁt from treatment
with entecavir, tenofovir (according to the age of the patient)
or lamivudine (C2) [187]. Although the duration of treatment is
not deﬁned, continuation of antiviral therapy for at least
3 months after anti-HBs seroconversion or 1 year after anti-HBe
seroconversion may be recommended (C2) [8].
Pregnant women
No antiviral agent has been approved by the FDA for use in
pregnancy. Lamivudine and entecavir are classiﬁed pregnancy
class C by the FDA, while both tenofovir and telbivudine are
class B. Although interference with organogenesis secondary to
the activity of the drug on replication of mitochondrial DNA
cannot be excluded, data from the Antiretroviral Pregnancy Reg-
istry has shown no increased incidence of birth defects with the
use of lamivudine (3.1% when used during the ﬁrst trimester
and 2.7% during the second or third trimester) or tenofovir
(2.4% and 2%, respectively) compared to the CDC’s population-
based birth defects surveillance system (2.72% of total preva-
lence) [134]. PegIFN is contraindicated during pregnancy (A1).
Children of lamivudine-treated mothers have 13–23% lower
incidence of intrauterine infection and 1–2% lower mother-to-
child transmission rate [135,136]. Treatment with telbivudine
during the third trimester of pregnancy has proven effective inon and/or HCC development would allow early treatment without
ention. Large clinical trials are ongoing to assess whether this
nts
e on response to treatment (and to verify whether younger
eeds to be  in pediatrics
are in adults needs to be speed up. Among such drugs, PegIFNα
e management of pediatric CHB
o be better 
debated issue for both adult and pediatric patients. The right
f resistance to antivirals needs to be further studied in pediatric
ges of combination therapy need to be tested by large clinical
 populations is still largely based on experts’ opinion, with 
er of patients with these conditions, multicenter pediatric studies
clarified
defined
3 vol. 59 j 814–829
JOURNAL OF HEPATOLOGY
reducing maternal viral load and preventing perinatal transmis-
sion (0% vs. 8% in controls) [137]. No studies are yet available
for tenofovir. Nevertheless, in order to reduce the risk of
mother-to-child transmission, treatment of highly viraemic
(serum HBV DNA >106 IU/ml) HBsAg-positive women during
the last trimester of pregnancy with tenofovir is currently rec-
ommended because of its high genetic barrier to resistance
and the possibility to continue therapy post-partum if needed
(B1) [8]. Although no studies have been conducted in pregnant
teens, the same recommendations for treatment in the third tri-
mester of pregnancy may apply (C1).
Household contacts
The extreme resilience of HBV, which allows its survival for more
than a week on dry surfaces, is the cause of the signiﬁcant risk of
horizontal intrafamilial transmission. Counseling of HBV carriers
and vaccination of uninfected household members are therefore
essential [33,138]. Surprisingly, although between 8% and 24%
of household contacts of HBV infected subjects (children and
adults) have been reported to be HBsAg-positive [139–143], vac-
cination coverage in this high-risk group is still low (15–25%)
even in developed countries [141,144–146]. All household con-
tacts of an HBV infected child should be screened for HBsAg,
HBsAb, and HBcAb in order to offer vaccination to those without
protective antibody levels and diagnose those with a previously
unknown infection (C1).Conclusions
CHB is a mild disease in most children and adolescents. Never-
theless, a minority of patients is at risk of rapid disease progres-
sion and early development of complications, and a quarter of
infected individuals develop serious complications in adult life.
Treatment of patients with elevated ALT levels is overall satisfac-
tory, but several unsolved issues need to be addressed (Table 4).
IFN-a is still the treatment of choice for most children. Although
in specialized centres PegIFN is currently used, this drug cannot
be recommended until the results of ongoing trials become avail-
able. Licensing of highly-effective NA for older children and ado-
lescents has opened new possibilities of treatment. Nevertheless,
the risk of emergence of drug resistant strains is a public health
problem and a major long-term issue for young patients. Before
starting a child on NAs, therefore, the risks of treatment should
be carefully weighed against the possible beneﬁts, and treatment
should be offered only to those patients who need to be treated
and are likely to respond. While waiting for the results of ongoing
trials, immunotolerant patients should not be treated, but moni-
tored routinely to identify early signs of liver damage. As the
management of special patient populations is problematic and
not evidence-based, their referral to highly specialized centers
is highly recommended.Conﬂict of interest
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